Skip to main content

Table 2 Numbers of events and 2-year and 5-year disease-free survival (DFS) and overall survival (OS) relative to treatment arm (95% confidence intervals in brackets)

From: Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial

 

FEC → Doc

FEC → Doc/Gem

DFS

 Events

239

219

 2-year rate

0.95 (0.94, 0.96)

0.95 (0.94, 0.96)

 5-year rate

0.87 (0.85, 0.88)

0.87 (0.86, 0.89)

OS

 Events

140

129

 2-year rate

0.98 (0.97, 0.99)

0.98 (0.97, 0.98)

 5-year rate

0.93 (0.92, 0.94)

0.93 (0.91, 0.94)